DRUG DISCOVERY / THERAPEUTICS
The International Centre for Neurotherapeutics (ICNT)
The ICNT is a multi-disciplinary centre undertaking research into the fundamental mechanisms of neurotransmitter release and its control by voltage-activated K+ channels. Such a major initiative was launched to develop novel treatments for certain neuronal disorders, based on deciphering the molecular basis of abnormalities in synaptic transmission. The research is funded by Science Foundation Ireland, Allergan Inc. and the U.S. Government.
The research conducted by Prof. Oliver Dolly on the selective and potent inhibition of transmitter release by botulinum neurotoxins has underpinned their successful and worldwide clinical use in treating human dystonias, spasticity and other movement disorders, as well as autonomic neuronal abnormalities of secretory glands (e.g. hyper-hydrosis, -salivation and lacrimation etc.), over-active bladder (e.g. in spina bifida, spinal cord injuries and multiple sclerosis) and gastrointestinal tract (e.g. pyloric sphincter).
Current efforts are devoted to developing second generation homologues and tailoring their functional properties for novel therapies.
For more information please see http://www.dcu.ie/icnt/facilities.shtml
Molecular Therapeutics for Cancer Ireland (MTCI) is a Science Foundation Ireland funded Strategic Research Cluster and represents one of the largest biomedical research programmes to date in the oncology arena in Ireland (5.6 million euro, excluding overhead). Co-ordinated by Professor John Crown, MTCI comprises a multi-institutional partnership between 4 academic centres and affiliated teaching hospitals in Dublin, namely Dublin City University (lead), University College Dublin, Trinity College Dublin and the Royal College of Surgeons in Ireland, with demonstrated excellence in translational cancer research. In addition, MTCI benefits from close inter-sectoral collaboration with several major pharmaceutical/major biotech companies (e.g. Pfizer, Novartis, Roche, Amgen) and other industrial parties. The core strategic mission of MTCI is to exploit our understanding of the molecular determinants of response and resistance to targeted anti-cancer therapies towards improved treatment approaches.
For more information please see www.mtci/ie
For further information on partnering opportunities, please contact Ms. Emma O’Neill, Business Development Manager, Life Sciences, DCU
Email: firstname.lastname@example.org Tel: 00 353 1 700 7741